Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026

By LabMedica International staff writers
Posted on 21 Oct 2026

GeneDx (Gaithersburg, MD, USA) is presenting 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montreal, Canada. More...

The research examines how exome and genome sequencing can improve the diagnosis of rare diseases, support genomic newborn screening, and identify genetic causes of neurodevelopmental conditions.

The research focuses on five areas: AI-assisted genomic interpretation, broader clinical use of exome and genome sequencing, translation of genomic data into clinical insights, gene discovery, and equitable newborn screening. Nine abstracts address gene discovery through GeneDx Infinity, GeneMatcher, and global collaborations, while other studies examine the clinical and economic value of genomic testing as a first-line diagnostic approach.

One study from the GUARDIAN newborn screening program examines genomic screening results from more than 19,000 newborns representing diverse genetic ancestries. Researchers are evaluating screen-positive rates and genetic variant findings to better understand how population diversity influences genomic screening outcomes and inform broader implementation of newborn genomic testing.

Another study analyzes exome sequencing data from more than 100,000 individuals with autism to identify factors influencing molecular diagnostic yield. The research examines how genomic testing can detect underlying genetic conditions in patients with complex neurodevelopmental disorders, providing additional evidence to inform the clinical use of exome sequencing.

GeneDx is also presenting research on the use of machine learning to improve the interpretation of copy number variants (CNVs) detected through genomic sequencing. The approach uses dynamic feature reconstruction to prioritize clinically relevant variants, with artificial intelligence (AI) supporting expert review of genetic findings and helping streamline the analysis of complex genomic data.

Additional research focuses on identifying genes associated with developmental disorders. One analysis of 184,786 parent-child trios investigates more than 100 newly identified disease-associated genes and candidate haplolethal genes. Another study examines variants in the SFPQ gene associated with a dominant neurodevelopmental syndrome, expanding research into the genetic causes of rare conditions.

Other presentations explore the clinical significance of RNU4-2 variants and the use of genotype-first reanalysis to identify previously unrecognized genetic diagnoses. A separate study involving 25,000 individuals investigates the genetic architecture of microcephaly, examining how rare genetic variants contribute to abnormal brain development.

The broader research program includes studies of rare variant detection, structural genomic alterations, AI-assisted phenotype modeling, rapid neonatal genome sequencing, and cardiovascular genetics. Several analyses also examine the clinical and economic implications of using exome and genome sequencing as first-line diagnostic approaches for patients with suspected genetic disorders.

GeneDx’s research is supported by GeneDx Infinity, a large rare disease genomic dataset used to investigate genetic variation and identify disease-associated genes. The company's ExomeDx and GenomeDx tests analyze genetic information to help clinicians diagnose inherited conditions. The platform also supports research collaborations focused on gene discovery and genomic interpretation.

“Advancing genomic medicine means turning scientific discovery into meaningful answers for patients,” said Linda Genen, MD, MPH, Chief Medical Officer at GeneDx. She added that the company's clinical data, technology, and research collaborations are helping build evidence for making exome and genome sequencing more accessible and useful across medical specialties.

Related Links
GeneDx


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.